Welcome!

News Feed Item

twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate

twoXAR, Inc., an artificial intelligence (AI)-driven biopharmaceutical company, today announced that its candidate, TXR-411, has shown promising results in the db/db mouse model of type 2 diabetes (T2DM). TXR-411 is a molecule that twoXAR identified as having a high probability of being effective in treating T2DM. Proof-of-concept studies in the db/db mouse model were performed by Melior Discovery, a leading research provider of preclinical services that previously achieved positive Phase 2A results with its first-in-class T2DM drug, MLR-1023. The objective of these studies was to further demonstrate proof of concept of twoXAR’s AI platform as a discovery engine capable of uncovering new therapies across a diversified set of diseases.

“The TXR-411 data in the db/db model is impressive given that the initial examination of our candidate achieved an approximately 50 percent decrease in glucose levels, on par with rosiglitazone, without the weight gain associated with rosiglitazone,” said Isaac Hakim, Ph.D, Director of Preclinical Studies at twoXAR. “The reduced glucose and body weight maintenance is exciting in its own right, however, even more compelling is that we selected this disease, identified and shortlisted candidates, and generated efficacious preclinical results in less than three months.”

Nearly four hundred million patients suffer from T2DM globally, and the market size is expected to double by 2025. Given the complex and multifactorial origin of T2DM there remains a high unmet need for novel therapies that work by new mechanisms. Peroxisome Proliferator-Activated Receptor (PPAR) agonists, such as rosiglitazone, were once the leading therapeutic class (commercially) but have since largely been discontinued due to initially unrecognized safety issues. Diabetic therapies which target novel biological pathways may help to reduce the risk of common side effects while improving levels of efficacy. In addition, combination therapies of two and three complementary therapeutics are standard practice and further increase the need for new antidiabetic mechanisms.

Using a clinically translatable model of T2DM (db/db mice), the data showed that TXR-411 significantly reduced blood glucose levels and improved the results of oral glucose tolerance as effectively as rosiglitazone. These results were achieved without any of the weight gain that is associated with PPAR agonists like rosiglitazone. Seeing potentially promising results in the db/db model is meaningful as this model incorporates many aspects of human T2DM including hyperglycemia, obesity, and impaired beta-cell function.

“Over the last 12 months we have publicly announced positive preclinical proof-of-concept data in rheumatoid arthritis, liver cancer, and now type 2 diabetes,” said Andrew A. Radin, co-founder and CEO of twoXAR. “Across these studies we have seen that about 30 percent of the novel candidates we test in preclinical studies show statistically significant efficacy signals in the in vivo models’ respective endpoints.”

twoXAR computationally screened a library of more than 25,000 potential drug candidates. The three with the strongest evidence for potential efficacy and safety were selected for these studies. Each candidate was identified using twoXAR’s computational drug discovery platform which utilizes artificial intelligence to rapidly perform unbiased analyses of biological, chemical, and clinical data to predict and rank potentially efficacious drugs. This strategy offers a new route to unique intellectual property rights that allow for the rapid development of a drug while maximizing the opportunity to identify the most efficacious molecule.

Preclinical studies were conducted by researchers at Melior Discovery, under the direction of John Ciallella, Ph.D, Director of Research at Melior Discovery and Melior Pharmaceuticals.

About twoXAR

twoXAR is an artificial intelligence-driven biopharmaceutical company. The company leverages its computational platform to identify promising drug candidates, de-risks the opportunities through preclinical studies, and progresses drug candidates to the clinic through industry partnerships. Based in Palo Alto, California, the twoXAR team includes experts in drug discovery and development, biomedical informatics, computational biology, data science and software development. For more information please visit, www.twoXAR.com.

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
21st International Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy. Me...
"Tintri focuses on the Ops side of the DevOps, which basically is pushing more and more of the accessibility of the infrastructure to the developers and trying to get behind the scenes," explained Dhiraj Sehgal of Tintri in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"We do one of the best file systems in the world. We learned how to deal with Big Data many years ago and we implemented this knowledge into our software," explained Jakub Ratajczak, Business Development Manager at MooseFS, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
"Our strategy is to focus on the hyperscale providers - AWS, Azure, and Google. Over the last year we saw that a lot of developers need to learn how to do their job in the cloud and we see this DevOps movement that we are catering to with our content," stated Alessandro Fasan, Head of Global Sales at Cloud Academy, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
SYS-CON Events announced today that TMC has been named “Media Sponsor” of SYS-CON's 21st International Cloud Expo and Big Data at Cloud Expo, which will take place on Oct 31 – Nov 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. Global buyers rely on TMC’s content-driven marketplaces to make purchase decisions and navigate markets. Learn how we can help you reach your marketing goals.
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
Cloud Expo, Inc. has announced today that Andi Mann and Aruna Ravichandran have been named Co-Chairs of @DevOpsSummit at Cloud Expo Silicon Valley which will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. "DevOps is at the intersection of technology and business-optimizing tools, organizations and processes to bring measurable improvements in productivity and profitability," said Aruna Ravichandran, vice president, DevOps product and solutions marketing...
Managing mission-critical SAP systems and landscapes has never been easy. Add public cloud with its myriad of powerful cloud native services and this may not change any time soon. Public cloud offers exciting new possibilities for enterprise workloads. But to make use of these possibilities and capabilities, IT teams need to re-think everything they have done before. Otherwise, they will just end up using public cloud as a hosting platform for their workloads, aka known as “lift and shift.”
"MobiDev is a Ukraine-based software development company. We do mobile development, and we're specialists in that. But we do full stack software development for entrepreneurs, for emerging companies, and for enterprise ventures," explained Alan Winters, U.S. Head of Business Development at MobiDev, in this SYS-CON.tv interview at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.